financetom
Business
financetom
/
Business
/
Legacy Housing Corporation's Q2 revenue up 18%, beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Legacy Housing Corporation's Q2 revenue up 18%, beats estimates
Aug 7, 2025 2:01 PM

Overview

* Legacy Q2 2025 revenue rises 18%, beating analyst expectations, per LSEG data

* Net income for Q2 2025 declines 9.2% yr/yr, reflecting market uncertainties

* Company repurchased 260,635 shares for $5.8 mln, indicating confidence in long-term value

Result Drivers

* REVENUE GROWTH - Driven by higher average selling prices and increased unit volumes

* SHARE REPURCHASE - Company repurchased shares, indicating confidence in long-term value

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $50.20 $44 mln

Revenue mln (4

Analysts

)

Q2 Net $14.70

Income mln

Q2 Basic $0.61

EPS

Q2 $16.80

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the homebuilding peer group is "buy"

* Wall Street's median 12-month price target for Legacy Housing Corp ( LEGH ) is $30.00, about 21.1% above its August 6 closing price of $23.67

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%
Jun 3, 2024
03:53 AM EDT, 06/03/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that a phase 3 trial of Enhertu showed statistically significant and clinically meaningful improvement in treating certain types of metastatic breast cancer over chemotherapy. The patients included those with HR-positive, HER2-low metastatic breast cancer as well as the overall trial population of patients with HR-positive, HER2-low and...
ACM Research Insider Sold Shares Worth $1,947,356, According to a Recent SEC Filing
ACM Research Insider Sold Shares Worth $1,947,356, According to a Recent SEC Filing
Jun 3, 2024
03:53 AM EDT, 06/03/2024 (MT Newswires) -- David H Wang, 10% Owner, Director, Chief Executive Officer, President, on May 29, 2024, sold 86,090 shares in ACM Research ( ACMR ) for $1,947,356. Following the Form 4 filing with the SEC, Wang has control over a total of 1,449,858 shares of the company, with 504,018 shares held directly and 945,840 controlled...
Ideaya Biosciences Insider Sold Shares Worth $1,032,884, According to a Recent SEC Filing
Ideaya Biosciences Insider Sold Shares Worth $1,032,884, According to a Recent SEC Filing
Jun 3, 2024
03:56 AM EDT, 06/03/2024 (MT Newswires) -- Michael Anthony White, Chief Scientific Officer, on May 29, 2024, sold 28,500 shares in Ideaya Biosciences ( IDYA ) for $1,032,884. SEC Filing: https://www.sec.gov/Archives/edgar/data/1676725/000161071724000272/xslF345X03/form4.xml ...
Kontoor Brands Insider Sold Shares Worth $1,825,095, According to a Recent SEC Filing
Kontoor Brands Insider Sold Shares Worth $1,825,095, According to a Recent SEC Filing
Jun 3, 2024
03:57 AM EDT, 06/03/2024 (MT Newswires) -- Scott H Baxter, Director, Chair, President and Chief Executive Officer, on May 30, 2024, sold 25,332 shares in Kontoor Brands ( KTB ) for $1,825,095. Following the Form 4 filing with the SEC, Baxter has control over a total of 477,257 shares of the company, with 318,188 shares held directly and 159,069 controlled...
Copyright 2023-2026 - www.financetom.com All Rights Reserved